Paper Details

  1. Home
  2. Paper Details

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat.

Author: AiharaYosuke, AkahaneTakemi, FukuiHiroshi, IkenakaYasuhide, KajiKosuke, KawarataniHideto, KitadeMitsuteru, NamisakiTadashi, NoguchiRyuichi, ShiraiYusaku, TsujimotoTatsuhiro, YamazakiMasaharu, YanaseKoji, YoshiiJunichi, YoshijiHitoshi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Non-alcoholic steatohepatitis (NASH) can progress into liver fibrosis and cirrhosis. Finding promising new therapeutic agents requires an appropriate experimental model that incorporates insulin resistance.
Paper Details　
Original Abstract of the Article :
Apart from simple steatosis, the non-alcoholic steatohepatitis (NASH) can progress into liver fibrosis and cirrhosis. To date, however, no widely accepted therapeutic modalities have been established against NASH in the clinical practice. To find out promising new therapeutic agents, it is important...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686718/

データ提供：米国国立医学図書館（NLM）

Losartan's Potential in Non-Alcoholic Steatohepatitis (NASH)

This research investigates a crucial challenge in the field of [hepatology], focusing on the potential of losartan in the management of [non-alcoholic steatohepatitis (NASH)]. The study explored the effects of losartan, an angiotensin-II type 1 receptor blocker, on liver fibrosis development in a rat model of NASH. The researchers found that losartan effectively attenuated liver fibrosis, suggesting its potential as a therapeutic agent for NASH. This research contributes to the ongoing search for effective treatments for this growing health concern.

Losartan: A Potential Therapeutic Avenue for NASH

This study suggests that losartan, a widely used antihypertensive drug, could potentially offer therapeutic benefits for individuals with NASH. The findings encourage further research to evaluate its efficacy and safety in human trials, potentially paving the way for a new treatment option for this complex liver disease.

Understanding the Potential Benefits of Losartan for Liver Health

As a [doctor], I am fascinated by the potential of existing medications to address different health concerns. This research suggests that losartan, which is already used for hypertension, might also have therapeutic benefits for NASH. It is important to remember that these findings need to be validated in larger human studies before any clinical recommendations can be made.

Dr. Camel's Conclusion

This study explores the potential of losartan, an angiotensin-II type 1 receptor blocker, in attenuating liver fibrosis development in a rat model of NASH. The findings suggest its potential as a therapeutic agent for NASH, prompting further research to evaluate its efficacy and safety in human trials.
Date :
  1. Date Completed 2009-12-16
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

19416517

DOI: Digital Object Identifier

PMC2686718

Related Literature

Article Analysis
・Side Effects of losartan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.